These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32659784)

  • 21. Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.
    Young JG; Vatsa R; Murray EJ; Hernán MA
    Trials; 2019 Sep; 20(1):552. PubMed ID: 31488202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal dynamic treatment regime estimation using information extraction from unstructured clinical text.
    Zhou N; Brook RD; Dinov ID; Wang L
    Biom J; 2022 Apr; 64(4):805-817. PubMed ID: 35112726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian inference for optimal dynamic treatment regimes in practice.
    Rodriguez Duque D; Moodie EEM; Stephens DA
    Int J Biostat; 2023 Nov; 19(2):309-331. PubMed ID: 37192544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interim monitoring in sequential multiple assignment randomized trials.
    Wu L; Wang J; Wahed AS
    Biometrics; 2023 Mar; 79(1):368-380. PubMed ID: 34571583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel approach to assess dynamic treatment regimes embedded in a SMART with an ordinal outcome.
    Ghosh P; Yan X; Chakraborty B
    Stat Med; 2023 Mar; 42(7):1096-1111. PubMed ID: 36726310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design.
    Li X; Guo X; Fan X; Feng T; Wang C; Yao Z; Xu X; Chen Z; Wang H; Xie S; He J; Zhuo K; Xiang Q; Cen H; Wang J; Smith RC; Jin H; Keshavan MS; Marder SR; Davis JM; Jiang K; Xu Y; Liu D
    Schizophr Res; 2021 Apr; 230():87-94. PubMed ID: 33279374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restricted sub-tree learning to estimate an optimal dynamic treatment regime using observational data.
    Speth K; Wang L
    Stat Med; 2021 Nov; 40(26):5796-5812. PubMed ID: 34340264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing cluster-level dynamic treatment regimens using sequential, multiple assignment, randomized trials: Regression estimation and sample size considerations.
    NeCamp T; Kilbourne A; Almirall D
    Stat Methods Med Res; 2017 Aug; 26(4):1572-1589. PubMed ID: 28627310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic treatment regimes: practical design considerations.
    Lavori PW; Dawson R
    Clin Trials; 2004 Feb; 1(1):9-20. PubMed ID: 16281458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inference about the expected performance of a data-driven dynamic treatment regime.
    Chakraborty B; Laber EB; Zhao YQ
    Clin Trials; 2014 Aug; 11(4):408-417. PubMed ID: 24925083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the causal effect of treatment regimes for organ transplantation.
    Boatman JA; Vock DM
    Biometrics; 2018 Dec; 74(4):1407-1416. PubMed ID: 29992533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doubly robust estimation of optimal dynamic treatment regimes with multicategory treatments and survival outcomes.
    Zhang Z; Yi D; Fan Y
    Stat Med; 2022 Oct; 41(24):4903-4923. PubMed ID: 35948279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.
    Ruppert AS; Yin J; Davidian M; Tsiatis AA; Byrd JC; Woyach JA; Mandrekar SJ
    Ann Oncol; 2019 Apr; 30(4):542-550. PubMed ID: 30799502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic treatment regimes (DTRs) to study treatment sequencing in oncology: a scoping review protocol.
    Esteves S; Alves JM; Rodrigues PP; Gomes da Silva M
    BMJ Open; 2023 May; 13(5):e067192. PubMed ID: 37253495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient and robust approaches for analysis of sequential multiple assignment randomized trials: Illustration using the ADAPT-R trial.
    Montoya LM; Kosorok MR; Geng EH; Schwab J; Odeny TA; Petersen ML
    Biometrics; 2023 Sep; 79(3):2577-2591. PubMed ID: 36493463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-stage matching-adjusted indirect comparison.
    Remiro-Azócar A
    BMC Med Res Methodol; 2022 Aug; 22(1):217. PubMed ID: 35941551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Propensity score analysis with partially observed covariates: How should multiple imputation be used?
    Leyrat C; Seaman SR; White IR; Douglas I; Smeeth L; Kim J; Resche-Rigon M; Carpenter JR; Williamson EJ
    Stat Methods Med Res; 2019 Jan; 28(1):3-19. PubMed ID: 28573919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times.
    Xu Y; Müller P; Wahed AS; Thall PF
    J Am Stat Assoc; 2016; 111(515):921-935. PubMed ID: 28018015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: A two-stage stochastic dynamic treatment regime approach.
    Hagiwara Y; Shinozaki T; Mukai H; Matsuyama Y
    Biometrics; 2021 Jun; 77(2):702-714. PubMed ID: 32420624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of two-phase sampling data with semiparametric additive hazards models.
    Sun Y; Qian X; Shou Q; Gilbert PB
    Lifetime Data Anal; 2017 Jul; 23(3):377-399. PubMed ID: 26995733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.